P//A
Aging is the biggest risk factor for chronic disease.
The science to delay or reverse it is accelerating, but roadblocks—from funding gaps to regulatory hurdles—are slowing progress.
Phoenix Aerie exists to help break these barriers.
Funding
Funding
Global investments in healthy longevity are insufficient to address aging demographics
Government and philanthropic funding for longevity research remains disproportionately low
Aging-focused research often requires longer timelines than traditional investors are willing to tolerate
Science
Longevity research is still considered niche, but that sentiment is shifting rapidly.
Bottlenecks in the research include:
Reduced influx of fresh ideas
Low interconnectivity
A dearth of new talent
A lack of enough tools to analyze and tackle the issue from a variety of different angles
Translation
Therapeutics, biomarkers, and interventions often get stuck due to lack of funding, poor startup guidance, or unclear FDA pathways
Scientists are rarely trained in how to navigate biotech entrepreneurship or apply their research outside of academia.
Aging interventions often lack clear clinical endpoints, making it difficult to design trials that demonstrate effectiveness and secure regulatory approval.
Perception & Policy &
Perception & Policy &
Public perception still views aging’s negative effects as inevitable, not as solvable problems.
Without a cultural shift, longevity efforts will remain underfunded and underprioritized
Aging itself is not classified as a treatable condition, forcing longevity therapeutics to be tested against individual diseases rather than aging-related decline as a whole
Even if interventions prove effective, there is no established medical infrastructure to support longevity-focused treatments
Our Solution?
Build. Connect. Accelerate.
Build. Connect. Accelerate.
Phoenix Aerie is being built around a simple need: helping emerging longevity talent move from interest to orientation, and from orientation to contribution.
The next phase is focused on smaller, sharper pilot formats that support young people entering the field while generating useful signal for the broader longevity ecosystem.
Community: Serious spaces for students and early-career people drawn to aging, healthspan, and longevity.
Orientation: Clearer pathways through the science, institutions, bottlenecks, and opportunities shaping the field.
Connection: Links between emerging talent and mentors, peers, labs, startups, clinicians, funders, and ecosystem leaders.
Intelligence: Maps of recurring needs, open problems, and places where young contributors can meaningfully enter.